The file's text, extracted by GovTribe without its formatting.
FedBizOpps Combined Synopsis/Solicitation Notice
CLASSIFICATION CODE
SUBJECT
CONTRACTING OFFICE'S
ZIP-CODE
SOLICITATION NUMBER
RESPONSE DATE (MM-DD-YYYY)
ARCHIVE
DAYS AFTER THE RESPONSE DATE
RECOVERY ACT FUNDS
SET-ASIDE
NAICS CODE
CONTRACTING OFFICE
ADDRESS
POINT OF CONTACT
(POC Information Automatically Filled from User Profile Unless Entered)
DESCRIPTION
See Attachment
AGENCY'S URL
URL DESCRIPTION
AGENCY CONTACT'S EMAIL
ADDRESS
EMAIL DESCRIPTION
ADDRESS
POSTAL CODE
COUNTRY
ADDITIONAL INFORMATION
GENERAL INFORMATION
PLACE OF PERFORMANCE
* = Required Field FedBizOpps Combined Synopsis/Solicitation Notice Rev. March 2010 Radiopharmaceuticals for the Montana VA Health Care System 80111 36C25918Q9874 09-05-2018 N 325412 Department of Veterans Affairs Network Contracting Office
NCO 19
6162 South Willow Drive, Suite 300 Greenwood Village CO 80111 Matt Zorch Montana VA Health Care System 3687 Veterans Drive Fort Harrison, MT 59636
USA
paul.zorch@va.gov paul.zorch@va.gov See attached document: Statement of Work - 25JUL2018.
See attached document: Schedule of Supplies.
Request for Quote (RFQ) #: 36C25918Q9874 Radiopharmaceuticals for the Montana VA Health Care System
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued. The Government reserves the right to make no award from this solicitation.
* The deadline for all questions is 4:00pm EST, August 29, 2018 All questions must be submitted in writing no later than the question cut-off date marked above. All questions will be answered officially through an amendment to the solicitation.
** Quotes are to be provided to Matt Zorch at paul.zorch no later than 4:00pm EST, September 5, 2018 Quotes shall not be hand carried. Faxed quotes shall not be accepted. Emailed quotes are the only method of submitted quotes (4MB email limit). The Government reserves the right to make award solely on initial Quotes received. Offerors bear the burden of ensuring that all portions of the offer (and any authorized amendments) reach the designated office before the deadline specified in the solicitation. This RFQ shall be completed in its entirety, and signed and dated, failure shall not be considered for award.
(ii) This is a Request for Quote (RFQ) and the solicitation number is 36C25918Q9874 The government anticipates awarding a firm-fixed price contract resulting from this solicitation.
(iii) This solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-99 effective July 16, 2018.
(iv) The North American Industrial Classification System (NAICS) code for this procurement is 325412 with a small business size standard of 1,250 employees. This solicitation is a 100% set-aside for Small Business concerns.
(v) List of Line Items;
(a.) The Contractor shall provide items on a unit dose basis, pre-drawn into a syringe, calibrated and delivered to the Nuclear Medicine department of the Montana VA Health Care System, 3687 Veterans Drive, Fort Harrison, Montana. Items will be required Monday through Friday during the hours of 7:30am to 4:00pm, and outside of these specified hours on an “as needed” basis.
(b.) Quantities listed are estimated usage only.
BASE YEAR: October 1, 2018 – September 30, 2019
| Line Item |
| Product Description |
| Method of Supply |
| Estimated Annual Quantity |
| Unit Price |
| Total Price |
| 0005 |
| Choletec/Mebrofenin |
| per dose |
| 10 |
| 0006 |
| Sulfur Colloid |
| Per dose |
| 0 |
| 0007 |
| Sulfur Colloid, Filtered |
| per dose |
| 3 |
| 0009 |
| Cardiolite/Sestamibi |
| Per dose |
| 0 |
| 0010 |
| Myoview/Tetrofosmin |
| per 1 mCi |
| 52 |
| 0012 |
| Tc-99m (Bulk) |
| per mCi |
| 0 |
| 0013 |
| Thallium-201 |
| per mCi |
| 0 |
| 0014 |
| Gallium-67 |
| per capsule |
| 0 |
| 0015 |
| I-123 (100uCi) |
| per capsule |
| 0 |
| 0016 |
| I-123 (200uCi) |
| each |
| 1 |
| 0017 |
| 20mCi Cobalt57 Sheet Source |
| Per vial |
| 17 |
| White Blood Cells |
| per study |
| 2 |
| 0019 |
| In-111 WBC |
| per study |
| 0 |
| 0020 |
| Ceretec |
| per occurrence |
| 2 |
Cold Kits
| 0022 |
| Choletec/Mebrofenin |
| per vial |
| 0 |
| 0023 |
| Hepatolite/Disofenin |
| per vial |
| 0 |
| 0027 |
| Sulfur Colloid |
| per vial |
| 0 |
| 0028 |
| Kinevac/Sincalide/CCK |
| per vial |
| 0 |
| 0032 |
| Cardiolite/Sestamibi |
| Per vial |
| 0 |
| 0033 |
| Myoview/Tetrofosmin |
| Per vial |
| 0 |
Incidentals
| 0034 |
| Persantine |
| per dose |
| 0 |
| 0036 |
| Dobutamine |
| per dose |
| 0 |
TOTAL BASE YEAR:
OPTION YEAR 1: October 1, 2019 – September 30, 2020
| Line Item |
| Product Description |
| Method of Supply |
| Estimated Annual Quantity |
| Unit Price |
| Total Price |
| 1005 |
| Choletec/Mebrofenin |
| per dose |
| 10 |
| 1006 |
| Sulfur Colloid |
| Per dose |
| 0 |
| 1007 |
| Sulfur Colloid, Filtered |
| per dose |
| 3 |
| 1009 |
| Cardiolite/Sestamibi |
| Per dose |
| 0 |
| 1010 |
| Myoview/Tetrofosmin |
| per 1 mCi |
| 52 |
| 1012 |
| Tc-99m (Bulk) |
| per mCi |
| 0 |
| 1013 |
| Thallium-201 |
| per mCi |
| 0 |
| 1014 |
| Gallium-67 |
| per capsule |
| 0 |
| 1015 |
| I-123 (100uCi) |
| per capsule |
| 0 |
| 1016 |
| I-123 (200uCi) |
| each |
| 1 |
| 1017 |
| 20mCi Cobalt57 Sheet Source |
| Per vial |
| 17 |
| White Blood Cells |
| per study |
| 2 |
| 1019 |
| In-111 WBC |
| per study |
| 0 |
| 1020 |
| Ceretec |
| per occurrence |
| 2 |
Cold Kits
| 1022 |
| Choletec/Mebrofenin |
| per vial |
| 0 |
| 1023 |
| Hepatolite/Disofenin |
| per vial |
| 0 |
| 1027 |
| Sulfur Colloid |
| per vial |
| 0 |
| 1028 |
| Kinevac/Sincalide/CCK |
| per vial |
| 0 |
| 1032 |
| Cardiolite/Sestamibi |
| Per vial |
| 0 |
| 1033 |
| Myoview/Tetrofosmin |
| Per vial |
| 0 |
Incidentals
| 1034 |
| Persantine |
| per dose |
| 0 |
| 1036 |
| Dobutamine |
| per dose |
| 0 |
TOTAL OPTION YEAR 1:
OPTION YEAR 2: October 1, 2020 – September 30, 2021
| Line Item |
| Product Description |
| Method of Supply |
| Estimated Annual Quantity |
| Unit Price |
| Total Price |
| 2005 |
| Choletec/Mebrofenin |
| per dose |
| 10 |
| 2006 |
| Sulfur Colloid |
| Per dose |
| 0 |
| 2007 |
| Sulfur Colloid, Filtered |
| per dose |
| 3 |
| 2009 |
| Cardiolite/Sestamibi |
| Per dose |
| 0 |
| 2010 |
| Myoview/Tetrofosmin |
| per 1 mCi |
| 52 |
| 2012 |
| Tc-99m (Bulk) |
| per mCi |
| 0 |
| 2013 |
| Thallium-201 |
| per mCi |
| 0 |
| 2014 |
| Gallium-67 |
| per capsule |
| 0 |
| 2015 |
| I-123 (100uCi) |
| per capsule |
| 0 |
| 2016 |
| I-123 (200uCi) |
| each |
| 1 |
| 2017 |
| 20mCi Cobalt57 Sheet Source |
| Per vial |
| 17 |
| White Blood Cells |
| per study |
| 2 |
| 2019 |
| In-111 WBC |
| per study |
| 0 |
| 2020 |
| Ceretec |
| per occurrence |
| 2 |
Cold Kits
| 2022 |
| Choletec/Mebrofenin |
| per vial |
| 0 |
| 2023 |
| Hepatolite/Disofenin |
| per vial |
| 0 |
| 2027 |
| Sulfur Colloid |
| per vial |
| 0 |
| 2028 |
| Kinevac/Sincalide/CCK |
| per vial |
| 0 |
| 2032 |
| Cardiolite/Sestamibi |
| Per vial |
| 0 |
| 2033 |
| Myoview/Tetrofosmin |
| Per vial |
| 0 |
Incidentals
| 2034 |
| Persantine |
| per dose |
| 0 |
| 2036 |
| Dobutamine |
| per dose |
| 0 |
TOTAL OPTION YEAR :
OPTION YEAR 3: October 1, 2021 – September 30, 2022
| Line Item |
| Product Description |
| Method of Supply |
| Estimated Annual Quantity |
| Unit Price |
| Total Price |
| 3005 |
| Choletec/Mebrofenin |
| per dose |
| 10 |
| 3006 |
| Sulfur Colloid |
| Per dose |
| 0 |
| 3007 |
| Sulfur Colloid, Filtered |
| per dose |
| 3 |
| 3009 |
| Cardiolite/Sestamibi |
| Per dose |
| 0 |
| 3010 |
| Myoview/Tetrofosmin |
| per 1 mCi |
| 52 |
| 3012 |
| Tc-99m (Bulk) |
| per mCi |
| 0 |
| 3013 |
| Thallium-201 |
| per mCi |
| 0 |
| 3014 |
| Gallium-67 |
| per capsule |
| 0 |
| 3015 |
| I-123 (100uCi) |
| per capsule |
| 0 |
| 3016 |
| I-123 (200uCi) |
| each |
| 1 |
| 3017 |
| 20mCi Cobalt57 Sheet Source |
| Per vial |
| 17 |
| White Blood Cells |
| per study |
| 2 |
| 3019 |
| In-111 WBC |
| per study |
| 0 |
| 3020 |
| Ceretec |
| per occurrence |
| 2 |
Cold Kits
| 3022 |
| Choletec/Mebrofenin |
| per vial |
| 0 |
| 3023 |
| Hepatolite/Disofenin |
| per vial |
| 0 |
| 3027 |
| Sulfur Colloid |
| per vial |
| 0 |
| 3028 |
| Kinevac/Sincalide/CCK |
| per vial |
| 0 |
| 3032 |
| Cardiolite/Sestamibi |
| Per vial |
| 0 |
| 3033 |
| Myoview/Tetrofosmin |
| Per vial |
| 0 |
Incidentals
| 3034 |
| Persantine |
| per dose |
| 0 |
| 3036 |
| Dobutamine |
| per dose |
| 0 |
TOTAL OPTION YEAR 3:
OPTION YEAR 4: October 1, 2022 – September 30, 2023
| Line Item |
| Product Description |
| Method of Supply |
| Estimated Annual Quantity |
| Unit Price |
| Total Price |
| 4005 |
| Choletec/Mebrofenin |
| per dose |
| 10 |
| 4006 |
| Sulfur Colloid |
| Per dose |
| 0 |
| 4007 |
| Sulfur Colloid, Filtered |
| per dose |
| 3 |
| 4009 |
| Cardiolite/Sestamibi |
| Per dose |
| 0 |
| 4010 |
| Myoview/Tetrofosmin |
| per 1 mCi |
| 52 |
| 4012 |
| Tc-99m (Bulk) |
| per mCi |
| 0 |
| 4013 |
| Thallium-201 |
| per mCi |
| 0 |
| 4014 |
| Gallium-67 |
| per capsule |
| 0 |
| 4015 |
| I-123 (100uCi) |
| per capsule |
| 0 |
| 4016 |
| I-123 (200uCi) |
| each |
| 1 |
| 4017 |
| 20mCi Cobalt57 Sheet Source |
| Per vial |
| 17 |
| White Blood Cells |
| per study |
| 2 |
| 4019 |
| In-111 WBC |
| per study |
| 0 |
| 4020 |
| Ceretec |
| per occurrence |
| 2 |
Cold Kits
| 4022 |
| Choletec/Mebrofenin |
| per vial |
| 0 |
| 4023 |
| Hepatolite/Disofenin |
| per vial |
| 0 |
| 4027 |
| Sulfur Colloid |
| per vial |
| 0 |
| 4028 |
| Kinevac/Sincalide/CCK |
| per vial |
| 0 |
| 4032 |
| Cardiolite/Sestamibi |
| Per vial |
| 0 |
| 4033 |
| Myoview/Tetrofosmin |
| Per vial |
| 0 |
Incidentals
| 4034 |
| Persantine |
| per dose |
| 0 |
| 4036 |
| Dobutamine |
| per dose |
| 0 |
TOTAL OPTION YEAR 4:
GRAND TOTAL BASE PLUS ALL OPTION YEARS:
(c.) Description of Requirements for the items to be acquired (salient characteristics);
Reference the attached Statement of Work.
(d.) Delivery and acceptance is to be F.O.B Destination (FAR 52.247-34) at the Veterans Affairs Medical Center, located at 3687 Veterans Drive, Fort Harrison, MT 59636
(e.) 52.212-1, Instructions to Offerors--Commercial ADDENDUM to FAR 52.212-1 INSTRUCTIONS TO OFFERORS—COMMERCIAL
a. Gray market items are Original Equipment Manufacturer’s (OEM) goods sold through unauthorized channels in direct competition with authorized distributors. This procurement is for new OEM medical supplies, medical equipment and/or services contracts for maintenance of medical equipment (i.e. replacement parts) for VA Medical Centers. No remanufactures or gray market items will be acceptable.
b. Contractor shall be an OEM, authorized dealer, authorized distributor or authorized reseller for the proposed medical supplies, medical equipment and/or services contracts for maintenance of medical equipment (i.e. replacement parts), verified by an authorization letter or other documents from the OEM, such that the OEM’s warranty and service are provided and maintained by the OEM. All software licensing, warranty and service associated with the medical supplies, medical equipment and/or services contracts for maintenance of medical equipment shall be in accordance with the OEM terms and conditions.
c. The delivery of gray market items to the VA in the fulfillment of an order/award constitutes a breach of contract. Accordingly, the VA reserves the right enforce any of its contractual remedies. This includes termination of the contract or, solely at the VA’s election, allowing the Vendor to replace, at no cost to the Government, any remanufactured or gray market item(s) delivered to a VA medical facility upon discovery of such items.
d. Offerors providing an “or equal” product(s) must adhere to the terms in FAR 52.211-6. If an item in this solicitation is identified as “brand name or equal,” the purchase description reflects the characteristics and level of quality that will satisfy the Government’s needs. The salient physical, functional, or performance characteristics that “equal” products must meet are specified in the solicitation. To be considered for award, offers of “equal” products, including “equal” products of the brand name manufacturer, must—
i. Meet the salient physical, functional, or performance characteristic specified in this solicitation;
ii. Clearly identify the item by-
1. Brand name, if any and
2. Make or model number,
iii. Include descriptive literature such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer; and
iv. Clearly describe any modification the offeror plans to make in a product to make it conform to the solicitation requirements. Mark any descriptive material to clearly show the modification.
The contracting officer will evaluate “equal” products on the basis of information furnished by the offeror or identified in the offer and reasonably available to the contracting officer. The Contracting Officer is not responsible for locating or obtaining any information not identified in the offer. Unless the offeror clearly indicates in its offer that the product being offered is an “equal” product, the offeror shall provide the brand name product referenced in the solicitation
e. Any award made as a result of this solicitation will be made on an All or Nothing Basis.
f. State if quoted items are available and priced through contractors existing Government-wide Acquisition Contract (GWAC), GSA Multiple Award Schedule (MAS) contract, or VA-wide Acquisition Contract.
g. Contractors socioeconomic status must be verified in the VA Vendor Information Pages (VIP): https://www.vip.vetbiz.gov/. Unverified contractors will be considered non-responsive.
h. Contractors are warned against contacting any VA personnel other than the Contracting Officer and Contract Specialist prior to placement of any award made resulting from this RFQ. If such contact occurs and found to be prejudicial to competing contactors, the contractor making such contact may be excluded from award considerations.
i. All proprietary information shall be clearly and properly marked. If the Offeror submits annexes, documentation, attachments or the like, not specifically required by this solicitation, such will count against the Offeror’s page limitations unless otherwise indicated in the specific volume instructions below.
j. All information shall be confined to the appropriate file. The contractor shall confine submissions to essential matters, sufficient to define the quote and provide an adequate basis for evaluation. Contractors are responsible for including sufficient details, in a concise manner, to permit a complete and accurate evaluation of each quote. Any award made resulting from this solicitation will be made based on the best overall quote that is determined to be the best overall value to the Government, considering (I) Technical Capability and (II) price.
k. Respondents to this announcement shall submit their quote on Contractors Letterhead in accordance with FAR 52.212-1. Submission of quote shall include the following volumes: (I) Technical Capability (II) Price.
Volume I - Technical Capability
Technical Capability - The offeror shall provide a signed statement certifying that the quote submitted meets the technical capability specified in the Statement of Work.
The Technical Capability submission shall include copies of all required licenses defined in the Statement of Work.
Volume II – Price
Price - The offeror shall complete the pricing schedule provided in Section (v) above: Price/Cost Schedule.
(End of Addendum to 52.212-1)
(f.) 52.212-2, Evaluation--Commercial Items ADDENDUM to FAR 52.212-2 EVALUATION—COMMERCIAL ITEMS:
a. The government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the government, price and other factors considered. The following factors shall be used to evaluate offers:
All offers shall be evaluated using the evaluation factors described below and must address, at a minimum, all elements listed in the solicitation’s instructions to Offerors FAR 52.212-1 and addendum FAR 52.212-1
Technical Capability – The Government will evaluate quotes on the basis of whether or not the provided quote meets the technical capability specified in the Statement of Work. Technical Capability shall consist of meeting or exceeding the requirements in the Statement of Work.
Price – The Government will evaluate offers by adding all line item prices - the Total of All CLINS will be that sum. The Government may use various price analysis techniques and procedures to make a price reasonableness determination. Offers that do not meet or exceed the technical capability requirements of the statement of work shall not be selected regardless of price.
Options (if requested); The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s)
b. All Offerors are advised that, in the interest of efficiency, the Government reserves the right to conduct the review in the most effective manner. Specifically, the Government may first sort the quotes of all Offerors by price from lowest price to the highest. Thereafter, the Government will review the Technical Capability of the lowest priced quote only. If the lowest priced Offeror’s Technical Capability is determined to be acceptable and meets the requirements, the Government may make award to that Offeror without further reviews of the remaining Offerors’ Technical Capability. If the lowest priced Offeror’s Technical Capability is determined to not meet the requirement, then the Government may review the Technical Capability next lowest priced quote, and so forth and so on, until the Government reaches a quote that is determined to meet the Technical Capability requirements.
(End of Addendum to 52.212-2)
(g.) Offerors are advised to include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications – Commercial Items, with the offer.
(h.) 52.212-4, Contract Terms and Conditions--Commercial Items – applies to this acquisition
(i.) 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders--Commercial Items
FAR 52.212-5 applies to this acquisition with the following FAR clauses incorporated by reference;
| FAR 52.203-6 |
| Restrictions on Subcontractor Sales to the Government (SEPT 2006), with Alternate I (OCT 1995) (41 U.S.C. 4704 and 10 U.S.C. 2402) |
| FAR 52.204-10 |
| Reporting Executive Compensation & First-Tier Subcontract Awards (OCT 2016) (Pub. L. 109-282) (31 U.S.C. 6101 note) |
| FAR 52.209-6 |
| Protecting the Government’s Interest When Subcontracting with Contractors Debarred, Suspended, or Proposed for Debarment (OCT 2015) (31 U.S.C. 6101 note) |
| FAR 52.219-8 |
| Utilization of Small Business Concerns (NOV 2016) (15 U.S.C. 637(d)(2) and (3)); |
| FAR 52.219-28 |
| Post Award Small Business Program Representation (Jul 2013) (15 U.S.C 632(a)(2)) |
| FAR 52.222-3 |
| Convict Labor (June 2003) (E.O. 11755) |
| FAR 52.222-19 |
| Child Labor—Cooperation with Authorities and Remedies (OCT 2016) (E.O. 13126) |
| FAR 52.222-21 |
| Prohibition of Segregated Facilities (APR 2015) |
| FAR 52.222-26 |
| Equal Opportunity (SEP 2016) (E.O. 11246) |
| FAR 52.222-35 |
| Equal Opportunity for Veterans (OCT 2015) (38 U.S.C. 4212) |
| FAR 52.222-36 |
| Equal Opportunity for Workers with Disabilities (JUL 2014) (29 U.S.C. 793) |
| FAR 52.222-37 |
| Employment Reports on Veterans (FEB 2016) (38 U.S.C. 4212) |
| FAR 52.222-40 |
| Notification of Employee Rights Under the National Labor Relations Act (DEC 2010) (E.O. 13496) |
| FAR 52.222-50 |
| Combating Trafficking in Persons (MAR 2015) (22 U.S.C. chapter 78 and E.O. 13627) |
| FAR 52.223-18 |
| Encouraging Contractor Policies to Ban Text Messaging While Driving (AUG 2011) |
| FAR 52.225–5 |
| Trade Agreements (OCT 2016) (19 U.S.C. 2501, et seq., 19 U.S.C. 3301 note) |
| FAR 52.225-13 |
| Restrictions on Certain Foreign Purchases (JUN 2008) (E.O.'s, proclamations, and statutes administered by the Office of Foreign Assets Control of the Department of the Treasury) |
| FAR 52.232-34 |
| Payment by Electronic Funds Transfer—Other than System for Award Management (Jul 2013) (31 U.S.C. 3332) |
(j.) Additional contract requirements or terms and conditions:
52.232-18 Availability of Funds (Apr 1984)
Funds are not presently available for this contract. The Government’s obligation under this contract is contingent upon the availability of appropriated funds from which payment for contract purposes can be made. No legal liability on the part of the Government for any payment may arise until funds are made available to the Contracting Officer for this contract and until the Contractor receives notice of such availability, to be confirmed in writing by the Contracting Officer.
52.252-2, Clauses Incorporated by Reference (Feb 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es):
http://www.acquisition.gov/far/index.html http://www.va.gov/oal/library/vaar/
The following FAR clauses are incorporated by reference:
52.204-7 System for Award Management
The following VAAR clauses are to be incorporated by reference:
852.203-70 Commercial Advertising (JAN 2008); 852.232-72 Electronic Submission of Payment Requests (NOV 2012); 852.246-70 Guarantee (JAN 2008); 852.246-71 Inspection (JAN 2008)
52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998)
This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this/these address(es):
http://www.acquisition.gov/far/index.html (FAR) http://www.va.gov/oal/library/vaar/index.asp (VAAR)
The following FAR provisions are to be incorporated by reference:
The following VAAR provisions are to be incorporated by reference:
852.273-70 Late Offers (JAN 2003); 852.273-72 Alternate Evaluation (JAN 2003); and 852.273-74 Award Without Exchanges (JAN 2003).
(k.) The Defense Priorities and Allocations System (DPAS) does not apply.
(l.) Date and Time offers are due to Matt Zorch at paul.zorch@va.gov by 4:00pm EST, September 5.
(m.) Name and email of the individual to contact for information regarding the solicitation:
Matt Zorch paul.zorch@va.gov